Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785551 · ClinicalTrials.gov registry record · Phase 1
Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment
A Phase 1 study, sponsored by Mutual Pharmaceutical Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00785551 is a Phase 1 study that was terminated before completion, run by Mutual Pharmaceutical Company. The registered enrollment target is 5 participants.
The verdict
NCT00785551, a Phase 1 study, was terminated before completion, sponsored by Mutual Pharmaceutical Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The effects of mild or moderate renal impairment (creatinine clearance 30 to 50 ml/min or \>50 to 80 ml/min, respectively) on the pharmacokinetic profile of quinine and its active metabolite, 3'-hydroxyquinine, will be investigated. Safety and tolerability in healthy subjects versus those with mild to moderate renal impairment will be compared, as well.
Interventions
- DRUG quinine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00785551
The ClinicalTrials.gov registry entry for NCT00785551 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mutual Pharmaceutical Company, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which quinine sulfate is the first listed.
NCT00785551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00785551 about?
NCT00785551 is a clinical study titled "Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment". The effects of mild or moderate renal impairment (creatinine clearance 30 to 50 ml/min or \>50 to 80 ml/min, respectively) on the pharmacokinetic profile of quinine and its active metabolite, 3'-hydroxyquinine, will be investigated. Safety and tolerability in healthy subjects versus those with mild ...
What is the current status of trial NCT00785551?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2007-11. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00785551?
The interventions under investigation include: quinine sulfate (DRUG).
Who is sponsoring clinical trial NCT00785551?
This trial is sponsored by Mutual Pharmaceutical Company, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.